Expert opinion of the European Tuberculosis Laboratory Initiative core group members for the WHO European Region.
Antimicrobial Resistance and Infection Control 2014,3 :31
A compendium of TB REACH case studies, lessons learned and a monitoring and evaluation framework.
Accessed November 2017.
Blueprint for EECA countries, first edition
A WHO Guideline for Emergency Risk Communication (ERC) policy and practice.
Recent public health emergencies, such as the Ebola virus disease outbreak in West Africa (2014–2015), the emergence of the Zika virus syndrome in 2015–2016 and multi-country yellow fever outbreaks in Africa in 2016, h...ave highlighted major challenges and gaps in how risk is communicated during epidemics and other health emergencies. The challenges include the rapid transformation in communications technology, including the near-universal penetration of mobile telephones, the widespread use and increasingly powerful influence of digital media which has had an impact on ‘traditional’ media (newspapers, radio and television), and major changes in how people access and trust health information. Important gaps include considerations of context – the social, economic, political and cultural factors influencing people’s perception of risk and their risk-reduction behaviours.
more
Responding to a poliovirus event and outbreak, Part 1: General (SOPs) describes the general principles and steps to facilitate timely and effective responses to poliovirus events and outbreaks, and incorporate lessons learned from recent previous outbreak response efforts. This document summarizes r...oles and responsibilities of national governments and Global Polio Eradication Initiative (GPEI) partners.
Effective 01 November 2017 until 30 April 2018
more
The main objectives of the SOPs are to: (i) establish standards and timelines for response activities; and (ii) guide national governments and GPEI partners in key support functions.
This new version of the SOPs presents overall response requirements for dealing with type 1, 2 and 3 poliovirus fo...llowing monovalent type 2 oral polio vaccine (mOPV2) cessation. Version 2.4 will be valid until release of revised version 3.0 (anticipated May 2018).
more